{
  "study_id": "NCT00337103",
  "study_title": "Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane",
  "table_name": "Table 1",
  "table_title": "Patient Demographic and Baseline Clinical Characteristics (intent-to-treat population)",
  "footnotes": [
    "Abbreviations: ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, progesterone receptor.",
    "*Refractory was defined as progression within 60 days after taking the last dose.",
    "†Reported by at least 20% of the total population.",
    "‡Visceral/nonvisceral was determined by independent assessment."
  ],
  "groups": [
    {
      "name": "Eribulin",
      "n": 554
    },
    {
      "name": "Capecitabine",
      "n": 548
    }
  ],
  "characteristics": [
    {
      "original_label": "Age, years",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "header",
          "raw_string": "Age, years"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "header",
          "raw_string": "Age, years"
        }
      ]
    },
    {
      "original_label": "Median",
      "standardized_name": "Age, Median",
      "unit": "years",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "numeric_single",
          "value": 54.0,
          "raw_string": "54.0"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "numeric_single",
          "value": 53.0,
          "raw_string": "53.0"
        }
      ]
    },
    {
      "original_label": "Range",
      "standardized_name": "Age, Range",
      "unit": "years",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "numeric_mean_range",
          "range_min": 24.0,
          "range_max": 80.0,
          "raw_string": "24-80"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "numeric_mean_range",
          "range_min": 26.0,
          "range_max": 80.0,
          "raw_string": "26-80"
        }
      ]
    },
    {
      "original_label": "Race",
      "standardized_name": "Race",
      "category": "Demographics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "header",
          "raw_string": "Race"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "header",
          "raw_string": "Race"
        }
      ]
    },
    {
      "original_label": "White",
      "standardized_name": "Race: White",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 496.0,
          "percentage": 89.5,
          "raw_string": "496 | 89.5"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 495.0,
          "percentage": 90.3,
          "raw_string": "495 | 90.3"
        }
      ]
    },
    {
      "original_label": "Asian/Pacific Islander",
      "standardized_name": "Race: Asian/Pacific Islander",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 18.0,
          "percentage": 3.2,
          "raw_string": "18 | 3.2"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 18.0,
          "percentage": 3.3,
          "raw_string": "18 | 3.3"
        }
      ]
    },
    {
      "original_label": "Black or African American",
      "standardized_name": "Race: Black or African American",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 15.0,
          "percentage": 2.7,
          "raw_string": "15 | 2.7"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 16.0,
          "percentage": 2.9,
          "raw_string": "16 | 2.9"
        }
      ]
    },
    {
      "original_label": "Other",
      "standardized_name": "Race: Other",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 25.0,
          "percentage": 4.5,
          "raw_string": "25 | 4.5"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 19.0,
          "percentage": 3.5,
          "raw_string": "19 | 3.5"
        }
      ]
    },
    {
      "original_label": "Geographic region",
      "standardized_name": "Geographic Region",
      "category": "Demographics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "header",
          "raw_string": "Geographic region"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "header",
          "raw_string": "Geographic region"
        }
      ]
    },
    {
      "original_label": "Eastern Europe",
      "standardized_name": "Geographic Region: Eastern Europe",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Geographic Region",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 307.0,
          "percentage": 55.4,
          "raw_string": "307 | 55.4"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 305.0,
          "percentage": 55.7,
          "raw_string": "305 | 55.7"
        }
      ]
    },
    {
      "original_label": "Latin America",
      "standardized_name": "Geographic Region: Latin America",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Geographic Region",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 105.0,
          "percentage": 19.0,
          "raw_string": "105 | 19.0"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 104.0,
          "percentage": 19.0,
          "raw_string": "104 | 19.0"
        }
      ]
    },
    {
      "original_label": "Western Europe",
      "standardized_name": "Geographic Region: Western Europe",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Geographic Region",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 80.0,
          "percentage": 14.4,
          "raw_string": "80 | 14.4"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 77.0,
          "percentage": 14.1,
          "raw_string": "77 | 14.1"
        }
      ]
    },
    {
      "original_label": "North America",
      "standardized_name": "Geographic Region: North America",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Geographic Region",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 44.0,
          "percentage": 7.9,
          "raw_string": "44 | 7.9"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 43.0,
          "percentage": 7.8,
          "raw_string": "43 | 7.8"
        }
      ]
    },
    {
      "original_label": "Asia",
      "standardized_name": "Geographic Region: Asia",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Geographic Region",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 13.0,
          "percentage": 2.3,
          "raw_string": "13 | 2.3"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 12.0,
          "percentage": 2.2,
          "raw_string": "12 | 2.2"
        }
      ]
    },
    {
      "original_label": "South Africa",
      "standardized_name": "Geographic Region: South Africa",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Geographic Region",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 0.9,
          "raw_string": "5 | 0.9"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 7.0,
          "percentage": 1.3,
          "raw_string": "7 | 1.3"
        }
      ]
    },
    {
      "original_label": "ECOG performance status",
      "standardized_name": "ECOG Performance Status",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "header",
          "raw_string": "ECOG performance status"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "header",
          "raw_string": "ECOG performance status"
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG Performance Status: 0",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 250.0,
          "percentage": 45.1,
          "raw_string": "250 | 45.1"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 230.0,
          "percentage": 42.0,
          "raw_string": "230 | 42.0"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG Performance Status: 1",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 293.0,
          "percentage": 52.9,
          "raw_string": "293 | 52.9"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 301.0,
          "percentage": 54.9,
          "raw_string": "301 | 54.9"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "ECOG Performance Status: 2",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 11.0,
          "percentage": 2.0,
          "raw_string": "11 | 2.0"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 16.0,
          "percentage": 2.9,
          "raw_string": "16 | 2.9"
        }
      ]
    },
    {
      "original_label": "3",
      "standardized_name": "ECOG Performance Status: 3",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 | 0"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.2,
          "raw_string": "1 | 0.2"
        }
      ]
    },
    {
      "original_label": "No. of prior chemotherapy regimens",
      "standardized_name": "Number of Prior Chemotherapy Regimens",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "header",
          "raw_string": "No. of prior chemotherapy regimens"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "header",
          "raw_string": "No. of prior chemotherapy regimens"
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "Number of Prior Chemotherapy Regimens: 0",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Prior Chemotherapy Regimens",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.2,
          "raw_string": "1 | 0.2"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 | 0"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "Number of Prior Chemotherapy Regimens: 1",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Prior Chemotherapy Regimens",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 147.0,
          "percentage": 26.5,
          "raw_string": "147 | 26.5"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 153.0,
          "percentage": 27.9,
          "raw_string": "153 | 27.9"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "Number of Prior Chemotherapy Regimens: 2",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Prior Chemotherapy Regimens",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 319.0,
          "percentage": 57.6,
          "raw_string": "319 | 57.6"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 314.0,
          "percentage": 57.3,
          "raw_string": "314 | 57.3"
        }
      ]
    },
    {
      "original_label": "3",
      "standardized_name": "Number of Prior Chemotherapy Regimens: 3",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Prior Chemotherapy Regimens",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 84.0,
          "percentage": 15.2,
          "raw_string": "84 | 15.2"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 78.0,
          "percentage": 14.2,
          "raw_string": "78 | 14.2"
        }
      ]
    },
    {
      "original_label": "4",
      "standardized_name": "Number of Prior Chemotherapy Regimens: 4",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Prior Chemotherapy Regimens",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 0.5,
          "raw_string": "3 | 0.5"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 0.4,
          "raw_string": "2 | 0.4"
        }
      ]
    },
    {
      "original_label": "5",
      "standardized_name": "Number of Prior Chemotherapy Regimens: 5",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Prior Chemotherapy Regimens",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 | 0"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.2,
          "raw_string": "1 | 0.2"
        }
      ]
    },
    {
      "original_label": "No. of prior chemotherapy regimens for advanced disease",
      "standardized_name": "Number of Prior Chemotherapy Regimens for Advanced Disease",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "header",
          "raw_string": "No. of prior chemotherapy regimens for advanced disease"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "header",
          "raw_string": "No. of prior chemotherapy regimens for advanced disease"
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "Number of Prior Chemotherapy Regimens for Advanced Disease: 0",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Prior Chemotherapy Regimens for Advanced Disease",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 116.0,
          "percentage": 20.9,
          "raw_string": "116 | 20.9"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 104.0,
          "percentage": 19.0,
          "raw_string": "104 | 19.0"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "Number of Prior Chemotherapy Regimens for Advanced Disease: 1",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Prior Chemotherapy Regimens for Advanced Disease",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 280.0,
          "percentage": 50.5,
          "raw_string": "280 | 50.5"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 293.0,
          "percentage": 53.5,
          "raw_string": "293 | 53.5"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "Number of Prior Chemotherapy Regimens for Advanced Disease: 2",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Prior Chemotherapy Regimens for Advanced Disease",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 154.0,
          "percentage": 27.8,
          "raw_string": "154 | 27.8"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 146.0,
          "percentage": 26.6,
          "raw_string": "146 | 26.6"
        }
      ]
    },
    {
      "original_label": "> 2",
      "standardized_name": "Number of Prior Chemotherapy Regimens for Advanced Disease: >2",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Prior Chemotherapy Regimens for Advanced Disease",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 0.7,
          "raw_string": "4 | 0.7"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 0.9,
          "raw_string": "5 | 0.9"
        }
      ]
    },
    {
      "original_label": "Refractory to treatment with:*",
      "standardized_name": "Refractory to Treatment",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "header",
          "raw_string": "Refractory to treatment with:*"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "header",
          "raw_string": "Refractory to treatment with:*"
        }
      ]
    },
    {
      "original_label": "Taxane",
      "standardized_name": "Refractory to Treatment: Taxane",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Refractory to Treatment",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 250.0,
          "percentage": 45.1,
          "raw_string": "250 | 45.1"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 260.0,
          "percentage": 47.4,
          "raw_string": "260 | 47.4"
        }
      ]
    },
    {
      "original_label": "Anthracycline",
      "standardized_name": "Refractory to Treatment: Anthracycline",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Refractory to Treatment",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 134.0,
          "percentage": 24.2,
          "raw_string": "134 | 24.2"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 139.0,
          "percentage": 25.4,
          "raw_string": "139 | 25.4"
        }
      ]
    },
    {
      "original_label": "Taxane and anthracycline",
      "standardized_name": "Refractory to Treatment: Taxane and Anthracycline",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Refractory to Treatment",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 91.0,
          "percentage": 16.4,
          "raw_string": "91 | 16.4"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 103.0,
          "percentage": 18.8,
          "raw_string": "103 | 18.8"
        }
      ]
    },
    {
      "original_label": "HER2 status",
      "standardized_name": "HER2 Status",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "header",
          "raw_string": "HER2 status"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "header",
          "raw_string": "HER2 status"
        }
      ]
    },
    {
      "original_label": "Positive",
      "standardized_name": "HER2 Status: Positive",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "HER2 Status",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 86.0,
          "percentage": 15.5,
          "raw_string": "86 | 15.5"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 83.0,
          "percentage": 15.1,
          "raw_string": "83 | 15.1"
        }
      ]
    },
    {
      "original_label": "Negative",
      "standardized_name": "HER2 Status: Negative",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "HER2 Status",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 375.0,
          "percentage": 67.7,
          "raw_string": "375 | 67.7"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 380.0,
          "percentage": 69.3,
          "raw_string": "380 | 69.3"
        }
      ]
    },
    {
      "original_label": "Not done",
      "standardized_name": "HER2 Status: Not Done",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "HER2 Status",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 93.0,
          "percentage": 16.8,
          "raw_string": "93 | 16.8"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 85.0,
          "percentage": 15.5,
          "raw_string": "85 | 15.5"
        }
      ]
    },
    {
      "original_label": "ER status",
      "standardized_name": "ER Status",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "header",
          "raw_string": "ER status"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "header",
          "raw_string": "ER status"
        }
      ]
    },
    {
      "original_label": "Positive",
      "standardized_name": "ER Status: Positive",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ER Status",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 259.0,
          "percentage": 46.8,
          "raw_string": "259 | 46.8"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 278.0,
          "percentage": 50.7,
          "raw_string": "278 | 50.7"
        }
      ]
    },
    {
      "original_label": "Negative",
      "standardized_name": "ER Status: Negative",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ER Status",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 233.0,
          "percentage": 42.1,
          "raw_string": "233 | 42.1"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 216.0,
          "percentage": 39.4,
          "raw_string": "216 | 39.4"
        }
      ]
    },
    {
      "original_label": "Not done",
      "standardized_name": "ER Status: Not Done",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ER Status",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 62.0,
          "percentage": 11.2,
          "raw_string": "62 | 11.2"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 54.0,
          "percentage": 9.9,
          "raw_string": "54 | 9.9"
        }
      ]
    },
    {
      "original_label": "PgR status",
      "standardized_name": "PgR Status",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "header",
          "raw_string": "PgR status"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "header",
          "raw_string": "PgR status"
        }
      ]
    },
    {
      "original_label": "Positive",
      "standardized_name": "PgR Status: Positive",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "PgR Status",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 227.0,
          "percentage": 41.0,
          "raw_string": "227 | 41.0"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 234.0,
          "percentage": 42.7,
          "raw_string": "234 | 42.7"
        }
      ]
    },
    {
      "original_label": "Negative",
      "standardized_name": "PgR Status: Negative",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "PgR Status",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 262.0,
          "percentage": 47.3,
          "raw_string": "262 | 47.3"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 248.0,
          "percentage": 45.3,
          "raw_string": "248 | 45.3"
        }
      ]
    },
    {
      "original_label": "Not done",
      "standardized_name": "PgR Status: Not Done",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "PgR Status",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 65.0,
          "percentage": 11.7,
          "raw_string": "65 | 11.7"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 66.0,
          "percentage": 12.0,
          "raw_string": "66 | 12.0"
        }
      ]
    },
    {
      "original_label": "Triple (HER2/ER/PgR) negative",
      "standardized_name": "Triple Negative Breast Cancer Status",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 150.0,
          "percentage": 27.1,
          "raw_string": "150 | 27.1"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 134.0,
          "percentage": 24.5,
          "raw_string": "134 | 24.5"
        }
      ]
    },
    {
      "original_label": "Most common metastatic sites†",
      "standardized_name": "Most Common Metastatic Sites",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "header",
          "raw_string": "Most common metastatic sites†"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "header",
          "raw_string": "Most common metastatic sites†"
        }
      ]
    },
    {
      "original_label": "Bone",
      "standardized_name": "Most Common Metastatic Sites: Bone",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Most Common Metastatic Sites",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 299.0,
          "percentage": 54.0,
          "raw_string": "299 | 54.0"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 308.0,
          "percentage": 56.2,
          "raw_string": "308 | 56.2"
        }
      ]
    },
    {
      "original_label": "Lung",
      "standardized_name": "Most Common Metastatic Sites: Lung",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Most Common Metastatic Sites",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 279.0,
          "percentage": 50.4,
          "raw_string": "279 | 50.4"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 280.0,
          "percentage": 51.1,
          "raw_string": "280 | 51.1"
        }
      ]
    },
    {
      "original_label": "Lymph nodes",
      "standardized_name": "Most Common Metastatic Sites: Lymph nodes",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Most Common Metastatic Sites",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 268.0,
          "percentage": 48.4,
          "raw_string": "268 | 48.4"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 274.0,
          "percentage": 50.0,
          "raw_string": "274 | 50.0"
        }
      ]
    },
    {
      "original_label": "Liver",
      "standardized_name": "Most Common Metastatic Sites: Liver",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Most Common Metastatic Sites",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 247.0,
          "percentage": 44.6,
          "raw_string": "247 | 44.6"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 271.0,
          "percentage": 49.5,
          "raw_string": "271 | 49.5"
        }
      ]
    },
    {
      "original_label": "No. of organs involved",
      "standardized_name": "Number of Organs Involved",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "header",
          "raw_string": "No. of organs involved"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "header",
          "raw_string": "No. of organs involved"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "Number of Organs Involved: 1",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Organs Involved",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 113.0,
          "percentage": 20.4,
          "raw_string": "113 | 20.4"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 92.0,
          "percentage": 16.8,
          "raw_string": "92 | 16.8"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "Number of Organs Involved: 2",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Organs Involved",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 174.0,
          "percentage": 31.4,
          "raw_string": "174 | 31.4"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 177.0,
          "percentage": 32.3,
          "raw_string": "177 | 32.3"
        }
      ]
    },
    {
      "original_label": "3",
      "standardized_name": "Number of Organs Involved: 3",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Organs Involved",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 153.0,
          "percentage": 27.6,
          "raw_string": "153 | 27.6"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 149.0,
          "percentage": 27.2,
          "raw_string": "149 | 27.2"
        }
      ]
    },
    {
      "original_label": "≥ 4",
      "standardized_name": "Number of Organs Involved: ≥4",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Organs Involved",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 114.0,
          "percentage": 20.6,
          "raw_string": "114 | 20.6"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 129.0,
          "percentage": 23.5,
          "raw_string": "129 | 23.5"
        }
      ]
    },
    {
      "original_label": "Missing",
      "standardized_name": "Number of Organs Involved: Missing",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Organs Involved",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 | 0"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.2,
          "raw_string": "1 | 0.2"
        }
      ]
    },
    {
      "original_label": "Site of disease‡",
      "standardized_name": "Site of Disease",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "header",
          "raw_string": "Site of disease‡"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "header",
          "raw_string": "Site of disease‡"
        }
      ]
    },
    {
      "original_label": "Visceral",
      "standardized_name": "Site of Disease: Visceral",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Site of Disease",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 467.0,
          "percentage": 84.3,
          "raw_string": "467 | 84.3"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 483.0,
          "percentage": 88.1,
          "raw_string": "483 | 88.1"
        }
      ]
    },
    {
      "original_label": "Nonvisceral only",
      "standardized_name": "Site of Disease: Nonvisceral Only",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Site of Disease",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 81.0,
          "percentage": 14.6,
          "raw_string": "81 | 14.6"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 61.0,
          "percentage": 11.1,
          "raw_string": "61 | 11.1"
        }
      ]
    },
    {
      "original_label": "Missing",
      "standardized_name": "Site of Disease: Missing",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Site of Disease",
      "group_data": [
        {
          "group_name": "Eribulin",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 1.1,
          "raw_string": "6 | 1.1"
        },
        {
          "group_name": "Capecitabine",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 0.7,
          "raw_string": "4 | 0.7"
        }
      ]
    }
  ]
}